Excessive-Dose Baricitinib for Severe Alopecia Areata Unresponsive to Conventional Therapy: A Real-World Assessment

1. Research Hypothesis:
Our study hypothesized that a higher-than-approved dose of baricitinib (6 mg daily) would demonstrate enhanced efficacy in promoting hair regrowth for patients with severe, treatment-refractory alopecia areata (AA), while maintaining an acceptable safety profile under close monitoring.
2. What the Data Shows & Notable Findings:
The shared dataset comprises deidentified clinical data from four female patients with severe AA (including alopecia universalis and totalis) who were unresponsive to conventional therapies. The data shows that:
Efficacy: Dose escalation to baricitinib 6 mg daily resulted in clinically meaningful hair regrowth (SALT score improvement) in 3 out of 4 patients (75%). One patient achieved complete regrowth (SALT 0).
Safety: The data captures the safety profile, showing transient and manageable laboratory abnormalities (e.g., mild anemia, thrombocytosis, elevated creatinine) in some patients, with no severe adverse events reported.
Key Finding: The data supports the concept that a dose-dependent response exists for baricitinib in AA, and 6 mg may overcome the therapeutic "ceiling" of the standard 4 mg dose for some refractory patients.
3. How the Data Was Gathered:
Data was collected retrospectively from electronic medical records at our institution. It includes:
Baseline characteristics: Age, disease duration, AA subtype, baseline SALT score.
Treatment history: Prior and concomitant therapies, baricitinib dosing modifications.
Longitudinal efficacy outcomes: Serial SALT scores recorded at clinical visits.
Safety monitoring: Serial results of standard laboratory tests (complete blood count, comprehensive metabolic panel).
All data was anonymized to protect patient privacy.
4. How to Interpret and Use the Data:
This dataset is primarily intended for validation of our reported findings and for secondary analysis, such as exploring trends in dose-response relationships or safety parameters in severe AA.
Users should note the inherent limitations of a small, retrospective case series. The findings are hypothesis-generating and require confirmation in larger, controlled studies.